Health Care • Biotechnology: Laboratory Analytical Instruments
$3.14 ▼ -0.07
(-2.18%)
MKT CAP: $399.9M • VOL: 7.51M
52W L $1 52W H $4
ROARABLE / RQD
D- • 41/100
PIOTROSKI
3 / 9
NAUT // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | $0 | $0 | $0 |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$59.0M | -$70.8M | -$63.7M |
| EBITDA (Normalized) | — | — | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$50.7M | -$59.1M | -$51.7M |
| Capital Expenditures (CapEx) | $1.3M | $2.1M | — |
| Free Cash Flow (FCF) | -$52.0M | -$61.3M | -$51.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | — | — | — |
| Cash & Short-Term Equivalents | $12.4M | $27.6M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $157.0M | $208.7M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR NAUT.